- Policy
- A second survey of expenditure reports was initiated
- by Lee, chang-jin Nov 27, 2020 06:26am
- A second survey of expenditure reports was initiated that documented the economic benefits that health authorities legally provided to medical personnel. The related industry is straining as meticulous inspections are expected to be carried out in order to strengthen the management of expenditure reports such as indirect rebates pointed out i
- Policy
- Contracts with modified indications are not terminated
- by Lee, Hye-Kyung Nov 26, 2020 08:58am
- The NHIS said that in the case of drugs that benefit from the RSA drug price negotiations, it cannot unilaterally terminate the existing contract to change the main indication. Based on the provisions of the NHIS on October 8th, the 'Detailed Operation Guidelines for Risk-Sharing Drug Price Negotiations', the contract cannot be terminated if
- Policy
- RSA's collateral period was reduced by 3 months
- by Lee, Hye-Kyung Nov 26, 2020 08:38am
- The amount of collateral that pharmaceutical companies have to pay when signing an RSA drug is expected to decrease by 25%. According to the 'Detailed Operation Guidelines for Drug Price Negotiation of the Risk Sharing Agreement' revised by The NHIS on October 8, the period of collateral has been changed from 12 months to 9 months. This is be
- Policy
- ₩965 billion for COVID-19 vaccine should be reflected
- by Lee, Jeong-Hwan Nov 26, 2020 06:03am
- People Power Party Rep. Kang Ki-yoon, urged the Democratic Party of Korea and the government to reflect the cost of COVID-19 vaccine in next year's budget so that the nation can get COVID-19 vaccine. Earlier, a bill containing COVID-19 vaccine budget of &8361;965 billion was voted in the Budget Adjustment Subcommittee of the Health and W
- Policy
- NSCLC treatment Vizimpro coverage effective from December
- by Lee, Hye-Kyung Nov 25, 2020 06:26am
- The healthcare reimbursement on Pfizer’s non-small cell lung cancer (NSCLC) treatment Vizimpro (dacomitinib) would be granted from Dec. 1. But the drug has to pass the Ministry of Health and Welfare (MOHW) Health Insurance Policy Deliberation Committee (HIPDC) on Nov. 27 to be fully approved. Prior to the HIPDC deliberation, the Health
- Policy
- The duration of administration of Maviret was reduced
- by Kim, Jung-Ju Nov 25, 2020 06:24am
- A plan to reduce the dosing period of Maviret (Glecaprevir/Pibrentasvir), a chronic hepatitis C virus treatment in Korea, from 12 weeks to 8 weeks in patients with chronic hepatitis 3 C infection in adults with targeted cirrhosis. Is promoted. Sumatriptan succinate, such as Myungin's migraine treatment Sumatran, doubles the daily reimbursed dose
- Policy
- Full listed drug reevaluation subjects to be revealed soon
- by Kim, Jung-Ju Nov 24, 2020 09:04am
- The government plans to finalize and announce the list of second listed drug reimbursement feasibility evaluation (clinical reevaluation) and the first full-fledged reevaluation in next month. However, conducting the reevaluation using international reference pricing (IRP) would be physically impossible in a mean time, because of clashing op
- Policy
- Why Daewoong Bio tests Gliatirin as a comparator
- by Lee, Tak-Sun Nov 24, 2020 09:03am
- Gliatamin (Daewoong Bio), the No. 1 sales item in the brain function improvement drug Choline alfoscerate, which is drawing attention as a re-evaluation issue, was newly approved for a bioequivalence test. This bioequivalence test, which is conducted on products with improved formulations, is attracting more attention due to the recent
- Policy
- The Health and Welfare Committee, postponed to 26th
- by Lee, Jeong-Hwan Nov 24, 2020 09:01am
- The Health and Welfare Committee of the National Assembly suffered a lapse of resolution of the budget for 2021 by the relevant government ministries on the afternoon of the 19th, and the subcommittee for legal review, which had been operating from this morning, also decided to suspend it without reopening. Ki-yoon Kang, a member of Peopl
- Policy
- "Let's develop new drugs with sales of ₩1 trillion"
- by Lee, Jeong-Hwan Nov 24, 2020 09:00am
- President Moon Jae-in announced that by 2025, the government will cultivate 47,000 human resources in the bio industry and increase the bio R&D budget to &8361;1.7 trillion, an additional &8361;400 billion from this year. In particular, he expressed his ambition to actively help the development of new blockbuster drugs with annual sales
